Lilly commits additional $4.5 billion across Indiana manufacturing sites, opens first dedicated genetic medicine facility
Lilly's Omvoh is the first and only IL-23p19 to demonstrate durable disease clearance in ulcerative colitis through four years
Lilly reports first-quarter 2026 financial results, raises full year guidance, and highlights momentum of new medicines
Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
Lilly's Jaypirca significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
FDA approves Lilly's Foundayo , the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions
Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz plus Zepbound delivered superior efficacy for adults with psoriatic arthritis and obesity
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients
Lilly's Olumiant recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
Silver Hammer Commences Summer Exploration Program at Its Strategically Located Fahey Silver Project in the Silver Valley of Idaho
